

## A composite computational model of liver glucose homeostasis. Part 2: Exploring system behaviour

Journal:	<i>Journal of the Royal Society Interface</i>
Manuscript ID:	rsif-2011-0783.R1
Article Type:	Research
Date Submitted by the Author:	19-Jan-2012
Complete List of Authors:	Bogle, David; University College London, Chemical Engineering Sumner, Tom; University College London, CoMPLEX Hetherington, James; University College London, CoMPLEX Seymour, Robert; University College London, Mathematics Li, Linzhong; University College London, CoMPLEX Varela Rey, Marta; University College London, CoMPLEX Yamaji, Sachi; University College London, CoMPLEX Saffrey, Peter; University College London, CoMPLEX Margoninski, Ofer; University College London, CoMPLEX Finkelstein, Anthony; University College London, Computer Science Warner, Anne; University College London, CoMPLEX
Subject:	Systems biology < CROSS-DISCIPLINARY SCIENCES
Keywords:	computational modeling, glucose homeostasis, liver, bifurcation analysis


 SCHOLARONE™  
Manuscripts

## A composite computational model of liver glucose homeostasis. Part 2: Exploring system behaviour

T. Sumner<sup>4</sup>, J. Hetherington<sup>1,2</sup>, R.M. Seymour<sup>1</sup>, L. Li<sup>1,2</sup>, M. Varela Rey<sup>2</sup>, S. Yamaji<sup>2</sup>,  
P. Saffrey<sup>3</sup>, O. Margoninski<sup>2,3</sup>, I.D.L. Bogle<sup>4†</sup>, A. Finkelstein<sup>3</sup>, A. Warner<sup>2</sup>

CoMPLEX (All authors) and <sup>1</sup>Mathematics, <sup>2</sup>Cell & Developmental Biology, <sup>3</sup>Computer Science, <sup>4</sup>Chemical Engineering, University College London, Gower Street, London WC1E 6BT

†Corresponding author: Professor David Bogle, Department of Chemical Engineering, University College London, Gower Street, London WC1E 6BT. email: d.bogle@ucl.ac.uk

**Running title:** Exploring Model of Glucose Homeostasis

**Key words:** computational modeling, glucose homeostasis, liver, bifurcation analysis

**Word count:** 3538

Present addresses:

M.Varela Rey: CICbioGUNE-CIBERehd, Metabolomic Unit, Parque Tecnológico de Vizcaya, Ed.801-A, C.P.48160-Derio, Vizcaya, Spain

S. Yamaji: Burnham Institute, North Torrey Pines Road, California USA.

J.Hetherington: Centre for Computational Science, Department of Chemistry, University College London, WC1H 0AJ

O.Margoninski: Verisign, Route des Arsenaux 41, Case Postale 249, Fribourg 1705 Switzerland

P.Saffrey: Division of Cancer Sciences and Molecular Pathology, Pathology Department, Western Infirmary, Dumbarton Road Glasgow United Kingdom G11 6NT

L.Li: Institute for Energy Technology, Instituttveien 18, 2007 Kjeller, Norway

T.Sumner, Institute for Animal Health, Pirbright Laboratory, Ash Road, Pirbright, Surrey, GU24 0NF

## 1. Abstract

Using a composite model of the glucose homeostasis system, consisting of seven interconnected submodels, we enumerate the possible behaviours of the model in response to variation of liver insulin sensitivity and dietary glucose variability. The model can reproduce published experimental manipulations of the glucose homeostasis system and clearly illustrates several important properties of glucose homeostasis - boundedness in model parameters of the region of efficient homeostasis, existence of an insulin sensitivity that allows effective homeostatic control, and the importance of transient and oscillatory behaviour in characterising homeostatic failure. Bifurcation analysis shows that the appearance of a stable limit cycle can be identified.

## 2. Introduction

Complex biological systems involve many interacting phenomena which often need to be explored together to understand system behaviour. In a companion paper [1] we presented a composite model of glucose homeostasis using seven distinct validated models combined together in a model management system [2]. The power of this approach is that it permits the use of ordinary differential equation models from a wide range of sources and allows models to be reused and replaced easily to test alternative hypotheses. There have been few comprehensive system level models of physiological systems covering many scales [3]. However the ability to tie biological phenomena to system level behaviour, particularly in clinical applications where most information is obtained from various parts of the system, will be important in the future.

The seven component models for glucose homeostasis which constitute the composite model presented in [1] are as follows: (A) Glucagon Receptor Model for the activation of a G-protein coupled receptor by a hormone stimulus, (B) Calcium Model for the calcium signalling pathway activated by IP<sub>3</sub>, (C) Cyclic AMP model representing the activation of the G-protein  $\alpha$ -subunit of the Glycogen Receptor Model, (D) Insulin Model for the insulin receptor and associated pathway, (E) Blood Model to describe the movements of glucose between the blood, the liver and the pancreas, (F) Glycogenolysis Model representing

1  
2  
3 glycogen breakdown and synthesis, and (G) Pancreas Model for the production of the  
4 hormones glucagon and insulin. The detailed models are given in [1], Appendix A. All  
5 models are available at <http://www.compbio.org./models.html>  
6  
7

8  
9  
10 The model was validated against data for the homeostatic response to a range of glucose  
11 challenges, to demonstrate the existence and correct behaviour of ultradian oscillations under  
12 appropriate conditions, and to match observed experimental behaviour in response to a  
13 glucagon challenge [4].  
14  
15

16  
17  
18 Continuous measurement of glucose has demonstrated the presence of ultradian blood  
19 glucose oscillations [5,6]. Although originally considered to have their genesis in the  
20 pancreas there has been increasing interest in the role of the liver. In the companion paper [1]  
21 we used the composite model to confirm that this phenomenon occurs as a result of feedback  
22 between pancreas and liver, first identified by Sturis et al. [7]. However it has not been  
23 possible until now to undertake a more comprehensive analysis of the oscillatory behaviour  
24 of the composite system and this is developed in this paper.  
25  
26  
27  
28  
29

30  
31 Specifically, here we explore the behaviour of the composite model in response to a range of  
32 glucose challenges. We focus on insulin sensitivity because this is the variable that is most  
33 susceptible to lifestyle changes and most affected by diet. It therefore has the biggest  
34 impact on human health. In particular we seek to ascertain the quantitative behaviour of the  
35 expected ultradian oscillations to demonstrate the power of using systems biology models.  
36  
37  
38  
39  
40  
41

### 42 **3. Exploring System Behaviour**

43  
44  
45

46 In order to explore the system's oscillatory behaviour, the qualitative and quantitative  
47 behaviour of the blood glucose output was explored in the plane of parameter space described  
48 by the external glucose stimulus,  $M$ , and the threshold value for the Hill function describing  
49 the hepatocyte insulin response,  $t_I$ .  $M$  is the glucose input to the Blood Cell Glucose  
50 Transport model (Model E of [1]), and  $t_I$  models the resistance of action by hepatocytes to  
51 insulin in the Insulin model (Model D of [1]). The correct response of the liver to insulin is  
52 important in the regulation of blood glucose. In particular, insulin resistance in which the  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 response of the liver to insulin is below the normal level is a major cause of type 2 diabetes,  
4 which accounts for over 90% of diabetes cases globally [8].  
5  
6  
7

8 In all cases  $M(t)$  is modelled as a step-function describing a sudden-onset, subsequently  
9 sustained glucose input. Also a step function is the normal test for dynamic systems to  
10 demonstrate significant effects in a consistent manner. Instead of insulin resistance, it is  
11 more useful to refer to insulin sensitivity which is given by  $1 - t_I$  and this value is used in the  
12 graphs presented in this paper. Fig 1 shows three example outputs of the model for different  
13 values of  $t_I$ : stable fixed point solution, oscillatory solution and stable fixed point solution  
14 reached via a transient overshoot. Our previous paper [1] gave a series of specific time  
15 course results using the model: figure 6 showed the formation of the limit cycle, fig 9 time  
16 courses for various values of glucose demand, and fig 10 response to a glucagon challenge.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 FIGURE 1 NEAR HERE  
29  
30

31 The parameter  $t_I$  is a derived one so it is instructive to determine how it relates to normal and  
32 diabetic states. In most studies insulin resistance was inferred from insulin or peptide  
33 measurements and was not directly measured [9]. Weyer et al [9] give the following ranges  
34 for insulin: fasting healthy Caucasians  $23 \pm 9$  micro-Unit  $l^{-1}$ ; fasting diabetic  $44 \pm 21$  micro-Unit  
35  $l^{-1}$ ; and 2 hours after a meal healthy  $100 \pm 98$  micro-Unit  $l^{-1}$  and diabetic  $242 \pm 204$  micro-Unit  
36  $l^{-1}$ . A Unit is 45  $\mu g$  of insulin. We have assumed that our units of insulin are at the  
37 maximum normal levels produced by the pancreas (see [1] supplementary material) and have  
38 assumed that the 2 hour data for a diabetic patient would be approximately equal to this. For  
39 our model a value of  $t_I$  of 1 would be approximately be 240 micro-Unit  $l^{-1}$  and  $t_I$  of 0.5  
40 approximately 120 micro-Unit  $l^{-1}$  which is somewhat above the normal level.  
41  
42  
43  
44  
45  
46  
47  
48

49 A bifurcation analysis was undertaken to explore the changes in the behaviour of the  
50 composite model as  $M$  and  $t_I$  were varied. The analysis was performed using the bifurcation  
51 analysis package, AUTO [10].  
52  
53  
54  
55

56 FIGURE 2 NEAR HERE  
57  
58  
59  
60

1  
2  
3  
4 The bifurcation diagram in Fig 2 shows the stable solutions of the model with respect to  $t_I$  for  
5 three values of  $M = 0.5, 5$  and  $7.5 \mu\text{M}$  of blood glucose (as noted above the x-axis shows ( $I-$   
6  $t_I$ ), such that increasing values indicate increased sensitivity to insulin). For low values of  
7 insulin sensitivity there is a stable fixed point of blood glucose, the value of which depends  
8 on the value of  $M$ . As the sensitivity to insulin is increased the blood glucose output  
9 undergoes a Hopf bifurcation at which an oscillatory solution (a stable limit cycle) emerges  
10 from the stable fixed point. As the insulin sensitivity is increased further the mean blood  
11 glucose level (time averaged mean) decreases but with an associated increase in the  
12 amplitude of the ultradian oscillations. Insulin sensitivity therefore has a significant effect on  
13 the stable blood glucose level resulting from a sustained glucose input, with insulin acting to  
14 lower that level. This however, is at the cost of transient glucose (ultradian) oscillations.  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 The value of insulin sensitivity at which the Hopf bifurcation occurs also varies with the level  
25 of the external glucose challenge,  $M$ . For higher glucose inputs the onset of the limit cycle  
26 occurs at lower values of insulin sensitivity. The larger the glucose input the greater the  
27 production of insulin by the pancreas and the less sensitive the liver needs to be to observe  
28 ultradian oscillations.  
29  
30  
31  
32  
33

34  
35 FIGURE 3 NEAR HERE  
36

37  
38 Figure 3 shows that at low insulin sensitivity (high insulin resistance) the level of sustained  
39 glucose input has a significant effect on the stable blood glucose level. However at high  
40 sensitivities (low resistance) the mean level (time averaged mean) is not significantly affected  
41 but transient glucose (ultradian) oscillations occur particularly at the higher sensitivities (Fig  
42 2).  
43  
44  
45  
46  
47

48 When the glucose input  $M$  is driven above  $22.5 \mu\text{M/s}$ , in the model, the blood glucose level  
49 increases indefinitely. This does not occur *in vivo* where glucose in excess of that which can  
50 be converted into glycogen and stored is broken down to provide substrates for fat  
51 metabolism. The inclusion of the way in which excess glucose is handled is perhaps the most  
52 obvious extension to the composite model.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The model demonstrates the large transient first excursion in the ultradian oscillation, a  
4 feature observed in some of the available experimental studies (e.g. [7]). Most studies,  
5 however, concentrate on the long-term behaviour under continuous glucose stimulus. Since  
6 the magnitude and duration of the transients vary with the model parameters experimentally  
7 observed transients can provide information about the underlying physiology. This is  
8 illustrated in figure 4 (A and B). Figure 9 in [1] shows example time courses for  $M = 10$   $t_1 =$   
9  $0.8$  (low insulin sensitivity resulting in no oscillations) and  $M = 10$  and  $t_1 = 0.1$  (high  
10 sensitivity resulting in oscillations).  
11  
12  
13  
14  
15  
16

17  
18 The maximum glucose level reached during the transient response to external glucose is  
19 controlled by the glucose input, and is largely independent of insulin sensitivity (fig 4A).  
20 However the relative amplitude of the initial rise in blood glucose compared to the steady  
21 state oscillations (fig 4B) does depend on the sensitivity of the liver to insulin. A high initial  
22 transient can therefore be used to identify insulin insensitivity which may have consequences  
23 for diagnosis and treatment of disease.  
24  
25  
26  
27  
28

29  
30 FIGURE 4 NEAR HERE  
31

32  
33 From these results some general findings may be summarised as follows (see figure 5 which  
34 gives a schematic representation of the qualitative behaviour of the model with respect to  
35 variation in the glucose input parameter  $M$  and the insulin sensitivity parameter  $t_1$ ):  
36  
37  
38

39  
40 Small glucose inputs that do not take blood glucose above the threshold for insulin release  
41 from the pancreas can be accommodated by direct glucose control, shown by the light grey  
42 region in Fig 5.  
43  
44  
45

46  
47 For intermediate glucose inputs, even for a liver which is completely resistant to insulin (and  
48 hence not subject to pancreatic control), as found in severe Type 2 diabetes or in Type 1  
49 diabetes, where the pancreas fails to release insulin, direct glucose control always results in  
50 glycogen synthesis to stabilise blood glucose levels (fig 4A with insulin sensitivity at or near  
51 zero). With extreme hyperglycemia it is known that blood glucose levels may be as high as  
52  $20\text{mM}$  (see for example [11]). Abnormally high blood glucose levels are diagnosed for blood  
53 glucose concentrations greater than  $7\text{mM}$  and restoration of a steady state after a glucose  
54 bolus is extremely slow in patients. A high, stabilized value of blood glucose characterizes a  
55  
56  
57  
58  
59  
60

1  
2  
3 situation where the system cannot return to the glucose set point. This result may represent  
4 the situation when the liver is completely resistant to insulin, or, alternatively Type 1 diabetes  
5 where no insulin is generated by the pancreas. Our model suggests that pancreatic control of  
6 blood glucose is possible so long as the sensitivity of the liver insulin receptor is at or above  $t_l$   
7 = 0.8 ( $1 - t_l = 0.2$  as shown on fig 3) when maximum blood glucose is within the range where  
8 the pancreas is sensitive.  
9

10  
11  
12  
13  
14 For large, sustained glucose inputs, the model shows that blood glucose would increase  
15 without limit over time if there were no way of eliminating or utilizing the excess. In reality  
16 excess glucose is diverted into fat metabolism pathways.  
17  
18

19  
20  
21 For moderate glucose input and insulin resistance, pancreatic control results in good  
22 homeostasis, with low maximum blood glucose (the light grey region in fig 5). Insulin  
23 sensitivity above the normal range is characterized by under-damping of blood glucose  
24 oscillations.  
25  
26  
27

28  
29  
30 Increased sensitivity to insulin may occur as a result of an autoimmune reaction, or pituitary  
31 or adrenal insufficiency. The onset of oscillations in a glucose tolerance test could provide an  
32 early indicator of insulin hypersensitivity. Currently there is no clear consensus over the  
33 protocol for a glucose tolerance test. Most practitioners sample only once or twice following  
34 the administration of glucose and there is no standard advice over the appropriate timing. In  
35 order to reveal the oscillations, it would be necessary to sample several times over two or  
36 three hours to reveal the temporal picture. Although individual variation will be considerable,  
37 we suggest that sampling for 2 to 3 hours at half hourly intervals would reveal the temporal  
38 pattern of the response and indicate whether the response is oscillatory. Oscillations would  
39 alert the clinician early to the possibility of a change in insulin sensitivity.  
40  
41  
42  
43  
44  
45  
46

47  
48 A large transient excursion during the first oscillation, significantly larger than subsequent  
49 oscillations, also indicates insulin hypersensitivity. High insulin sensitivity can be a problem  
50 for individuals on insulin therapy for diabetes mellitus as a consequence of an autoimmune  
51 response. The consequences of insulin hypersensitivity are particularly marked in relation to  
52 fat metabolism ([12], [13], [14]).  
53  
54  
55  
56

#### 57 **4. Discussion**

58  
59  
60



1  
2  
3  
4 The results we obtain from analyzing the composite model suggest that analysis of the  
5 relationship between the glucose stimulus and the magnitude of the resultant blood  
6 glucose excursion may provide a more effective indicator of homeostatic capability than  
7 considering the glucose increase resulting from a single glucose input. In our model effective  
8 homeostasis occurs over a region of glucose inputs where increasing glucose input does not  
9 result in increased blood glucose level. Further development of the model may reveal  
10 potential early clinical indicators of altered insulin resistance. This could be valuable since  
11 the model shows that unless insulin resistance increases by more than  $t_I = 0.8$  ( $1 - t_I = 0.2$ ),  
12 direct glucose control will compensate. Increased resistance indicates diabetes, while  
13 increased sensitivity may reflect an autoimmune response to insulin or pituitary or adrenal  
14 insufficiency. Both conditions benefit from early recognition and therefore treatment. For  
15 example, the analysis of transients in glucose tolerance tests may have diagnostic power for  
16 the study of pathologies of glucose metabolism (see fig 4B) which reveals that the magnitude  
17 of the transient response is determined by insulin sensitivity.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 Finally the model supports the proposal that ultradian oscillations result from system level  
30 behaviour of feedback between liver and pancreas. Consider a situation in which glucose is  
31 fed into the blood at a constant positive rate  $M$ . This results in the indefinite growth of blood  
32 glucose concentration, other things being equal. However, when blood glucose concentration  
33 has reached a threshold level, release of insulin by the pancreas is triggered. This in turn  
34 results in an increase in phosphorylated glycogen synthase kinase (GSK), and hence in the  
35 increased rate of conversion of blood glucose into glycogen in hepatocytes (Model F of [1],  
36 Appendix A.6). The increase in blood glucose concentration is then arrested, resulting in a  
37 stable equilibrium concentration, but may be reversed if GSK production is sufficiently  
38 sensitive to insulin (i.e. provided  $t_I$  is sufficiently *low* – Model D of [1], Appendix A.4,  
39 equation A.4.1). If this reversal is fast enough, then blood glucose concentration can drop  
40 rapidly below the threshold at which insulin is released by the pancreas. In the absence of  
41 insulin, GSK then also drops rapidly, and the rate of conversion of glucose into glycogen is  
42 therefore reduced. Since glucose is still being ingested at a constant rate, blood glucose  
43 concentration may then again increase, and the cycle begins again.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 This cycle of events leads to oscillations in blood glucose concentrations. These oscillations  
4 may be overdamped, or underdamped [15] or, result in a stable limit cycle as shown in Fig 2  
5 depending on  $M$  and other model parameters. For a given  $M$ , these outcomes depend  
6 essentially on the sensitivity of GSK to insulin. As the control parameter  $t_I$  decreases the  
7 insulin sensitivity increases and there is a sequence of bifurcations through resulting outcome  
8 blood glucose concentrations i.e. from stable equilibrium but with high glucose level to  
9 overdamped oscillations leading to lower stable equilibrium, to the appearance of a stable  
10 limit cycle with lower mean concentration, leading finally to physiologically unsustainable  
11 underdamped oscillations. We can demonstrate this computationally using the model.  
12  
13  
14  
15  
16  
17  
18

19 If we effectively remove the pancreas from the system, by setting the scaling factors between  
20 the pancreas and insulin models and pancreas and cAMP models to zero, the system does not  
21 produce ultradian oscillations in blood glucose for values of the external glucose input ( $M$ )  
22 for which oscillations were observed in the complete system. Removing the pancreas from  
23 the system is effectively equivalent to setting the insulin sensitivity of the liver to zero. In the  
24 first case (no pancreas) no insulin is produced and hence there is no response in the liver. In  
25 the second case (insulin sensitivity = 0) insulin may be produced by the pancreas but the liver  
26 is unable to respond to the hormone. The bifurcation analysis has shown that under these  
27 conditions oscillations do not occur (see figure 2 (bifurcation diagram)).  
28  
29  
30  
31  
32  
33  
34

35 If we incrementally increase the scaling between the pancreas and insulin models back to its  
36 original value we observe the reappearance of oscillatory solutions. The point at which this  
37 occurs depends on the glucose input ( $M$ ) and the sensitivity of the liver to insulin ( $1 - t_I$ ); the  
38 higher the insulin sensitivity the lower the scaling value required to produce ultradian  
39 oscillations. These results do not depend on the value of the glucagon scaling parameter  
40 because for positive glucose inputs the blood glucose level does not fall below the value  
41 required to trigger the production of glucagon in the pancreas model.  
42  
43  
44  
45  
46  
47

48 We can explore the role of the feedback of blood glucose on the pancreas by varying the  
49 parameters which govern the response of the pancreas to the changes in blood glucose. The  
50 production of hormones by the pancreas is modelled using threshold (or hill) functions. The  
51 parameters  $t_{I_g}$  and  $t_{L_g}$  determine the level of blood glucose above or below the reference value  
52 at which the pancreas releases insulin or glucagon respectively. Increasing these parameters  
53 represents the situation in which the pancreas is less sensitive to changes in blood glucose. As  
54  $t_{I_g}$  is increased for a given  $M$  and  $t_I$ , oscillations cease to exist as the pancreas does not  
55  
56  
57  
58  
59  
60

1  
2  
3 respond to the initial rise in blood glucose with the release of insulin. The more sensitive the  
4 liver is to insulin the greater the range of  $t_{lg}$  for which we observe oscillations (see Figure 6);  
5 the amount of insulin produced by the pancreas, even with a high glucose response threshold,  
6 is sufficient to trigger the regulation of GSK in the liver.  
7  
8  
9

10  
11  
12  
13  
14 FIGURE 6 NEAR HERE  
15  
16  
17

## 18 19 **5. Conclusions**

20  
21  
22  
23 This paper presents an exploration of the behaviour of the composite model of glucose  
24 homeostasis described in the companion paper [1]. We have explored the behaviour as a  
25 function of a range of glucose input values and also, since oscillatory behaviour is known to  
26 occur, we present a bifurcation analysis to provide quantitative information about the  
27 occurrence of these oscillations.  
28  
29  
30

31  
32  
33 Analysis of the composite model and its results in this and the companion paper [1] reveals  
34 that direct glucose control, determined by the capacity of the liver to store glucose, plays an  
35 important role in the control of glucose homeostasis. Deficiencies in hormonal control  
36 generated by, for example, a reduction in insulin sensitivity, can be accommodated through  
37 the direct control mechanism over a surprisingly wide range of insulin sensitivities. The  
38 analysis suggests that the consequences of reductions in the sensitivity of the insulin receptor  
39 do not become significant until receptor sensitivity has fallen below  $1 - t_1 = 0.2$ . The masking  
40 of clinically significant alterations in insulin sensitivity by the direct glucose control  
41 mechanism has important consequences, because delays in recognizing the early signs of  
42 diabetes may have consequences for treatment.  
43  
44  
45  
46  
47  
48  
49

50  
51  
52 The direct glucose control mechanism depends on the capacity of the liver to store glucose as  
53 glycogen, which provides a significant buffer to alterations in blood glucose however they  
54 may be generated. Glycogen storage diseases form a significant body of contributory causes  
55 to defects in glucose homeostasis, particularly when the defect resides within the liver, rather  
56  
57  
58  
59  
60

1  
2  
3 than the muscles. Analysis of the part played by direct glucose control in glucose homeostasis  
4 should improve understanding of both causes and consequences of glycogen storage disease.  
5 The model presented here will provide a relatively simple way of testing the physiological  
6 consequences of metabolic defects that underlie glycogen storage disease because there  
7 should be directly demonstrable and measurable consequences for glucose homeostasis. Any  
8 reduction in the capacity of the liver to store glucose in the form of glycogen will, because of  
9 the significant role in glucose homeostasis, exacerbate any consequences of glycogen storage  
10 diseases.  
11  
12  
13  
14  
15  
16

17  
18 The composite model presented here is one step in an ongoing process of developing more  
19 complete system models of liver function and enhancing modelling methodology. The current  
20 model already yields interesting results and provides a foundation for work including other  
21 important elements of liver physiology. An analysis of glycogen storage disease would be  
22 valuable. Obvious additions to the core model include: an elaboration of glucose metabolism  
23 and storage to represent the physiological transition towards fat metabolism as cellular  
24 glucose levels increase, and the representation of multiple hepatocytes with heterogeneous  
25 properties and linked to each other by gap junctions, to investigate the role of metabolic  
26 zonation in liver function. Our composite model could also be enhanced significantly by the  
27 inclusion of a more detailed model of the pancreas.  
28  
29  
30  
31  
32  
33  
34  
35

## 36 6. References

- 37  
38  
39  
40 [1] Hetherington J., Sumner T., Seymour R.M., Li L., Varela Rey M., Yamaj S., Saffrey  
41 P., Margoninski O., Bogle I.D.L., Finkelstein F., Warner A. (2011) A composite  
42 computational model of liver glucose homeostasis. Part 1: Building the composite model. J  
43 Roy Soc Interface. Published online before print June 15, 2011, doi: 10.1098/rsif.2011.0141  
44  
45 [2] Margoninski O, Saffrey P, Hetherington J, Li L, Finkelstein A & Warner A (2006). A  
46 specification language and a framework for the execution of composite models in systems  
47 biology. *LNCS Transactions on Computational Systems Biology* **VII. 4230**, 163 – 124  
48  
49 [3] Noble D (2002). Modeling the heart—from genes to cells to the whole organ.  
50 *Science* **5560**, 1678-1682.  
51  
52 [4] Lockton JA & Poucher SM (2007). Single dose glucagon (0.5 mg iv bolus)  
53 administration in healthy human volunteers is a robust model for assessment of  
54  
55  
56  
57  
58  
59  
60

- glycogenolysis: characterisation of the glucose excursion after glucagon challenge. *J Pharmacol Toxicol Methods* **55**, 86–90
- [5] Simon, C, Brandenberger, G and Follenius, M. (1987). Ultradian oscillations of Plasma Glucose, Insulin and C-Peptide in Man during continuous Enteral Nutrition. *J. Clin. Endocrinol and Metab.* **64**, 669- 674.
- [6] Simon C & Brandenberger G (2002). Ultradian oscillations of insulin secretion in humans. *Diabetes* **51** (Supplement 1), S258-S261
- [7] Sturis J, Polonsky KS, Mosekilde E & Cauter EV (1991). Computer model for mechanisms underlying ultradian oscillations of insulin and glucose. *Am J Physiol Endocrinol Metab* **260**, E801–E809.
- [8] P. Zimmet, K. G. M. M. Alberti & J. Shaw (2001), Global and societal implications of the diabetes epidemic, *Nature*, 414
- [9] Weyer C., Hanson R., Tataranni P.A., Bogardus C., and Pratley R.E. (2000) A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance. *Diabetes* **49** 2094-2101
- [10] Doedel E. (2007) AUTO-07p : Software for Continuation and Bifurcation Problems in Ordinary Differential Equations. <http://indy.cs.concordia.ca/auto/> Concordia University, Montreal, Canada.
- [11] Svendsen P. T., Lauritzen L, Søgaard, U. & Nerup J (1982). Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes. *Diabetologica* **23**, 403-405
- [12] De Bodo RC & Altszuler N (1958). Insulin hypersensitivity and physiological insulin antagonists. *Physiol.Rev.* **38**, 389 - 44
- [13] Weng, W & Breslow, JL (1996). Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility *PNAS* **93**(25), 14788-14794
- [14] Fujiwara Y, Hiroyama M, Sanbe A, Aoyagi T, Birumachi J, Yamauchi J, Tsujimoto G & Tanoue A (2007). Insulin hypersensitivity in mice lacking the V1b vasopressin receptor *J Physiol.* **584**(1), 235-244
- [15] Hetherington J, Warner A & Seymour RM (2006). Simplification and its consequences in biological modelling: conclusions from a study of calcium oscillations in hepatocytes. *Journal of The Royal Society – Interface* **10**, 319-331.

## 7. Acknowledgements

This work was funded as a Beacon Project of the United Kingdom Department of Trade and Industry (DTI). We thank the DTI for their support. T Sumner was funded by a CoMPLEX EPSRC Doctoral Training Centre Studentship. We have enjoyed useful discussions with Jonathan Ashmore and Rajiv Jalan.

For Review Only

## Figure Captions

Figure 1 – Sample model responses showing stable response ( $M= 7.5$ ,  $t_I = 0.6$ ), transient with damped oscillations ( $M= 7.5$ ,  $t_I = 0.5$ ) and stable limit cycle ( $M= 7.5$ ,  $t_I = 0.4$ )

Figure 2. – Bifurcation plot as  $t_I$  is varied for three values of  $M$  showing when Hopf bifurcations occur. Solid line indicates a stable fixed point, filled circles indicate the minimum and maximum values of the limit cycle. Insulin sensitivity is plotted as  $1-t_I$

Figure 3 - Final resting blood glucose concentration as a function of relative insulin resistance. For oscillatory solutions the mean value is shown. The curves represent various glucose inputs, from bottom to top,  $M = 0, 5, 7.5, 10, 15, 20, 22.5$

Figure 4 - Panel A: Maximum glucose value reached as a function of relative insulin resistance. Glucose input values and code for lines as in figure 3. Panel B: Amplitude of initial transient relative to steady state value defined as  $(x_{max}-x_{final})/x_{final}$ .  $M = 7.5$  ( $\bullet$ ), 10 ( $\square$ ), 15 ( $*$ ), 20 ( $\Delta$ ).

Figure 5 –The qualitative behaviours of the model as a function of insulin resistance and glucose input. When insulin resistance is high, homeostasis can be maintained by direct glucose control. As insulin resistance falls, homeostatic control is increasingly dominated by pancreatic release of insulin and glucagon, oscillations in blood glucose become increasingly prominent, and occur at progressively lower blood glucose levels.

Figure 6 - The y axis shows the value of  $t_{IG}$  at which model oscillations cease. For lower values the system oscillates.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 – Sample model responses showing stable response ( $M= 7.5, tI = 0.6$ ), transient with damped oscillations ( $M= 7.5, tI = 0.5$ ) and stable limit cycle ( $M= 7.5, tI = 0.4$ )






Figure 2. – Bifurcation plot as  $tI$  is varied for three values of  $M$  showing when Hopf bifurcations occur. Solid line indicates a stable fixed point, filled circles indicate the minimum and maximum values of the limit cycle. Insulin sensitivity is plotted as  $1-tI$

Only




Figure 3 - Final resting blood glucose concentration as a function of relative insulin resistance. For oscillatory solutions the mean value is shown. The curves represent various glucose inputs, from bottom to top,  $M = 0, 5, 7.5, 10, 15, 20, 22.5$





Figure 4 - Panel A: Maximum glucose value reached as a function of relative insulin resistance. Glucose input values and code for lines as in figure 3.



Panel B: Amplitude of initial transient relative to steady state value defined as  $(x_{\max} - x_{\text{final}}) / x_{\text{final}}$ .  $M = 7.5$  (.), 10 ( $\square$ ), 15 (\*), 20 ( $\Delta$ ).




Figure 5 –The qualitative behaviours of the model as a function of insulin resistance and glucose input.

When insulin resistance is high, homeostasis can be maintained by direct glucose control. As insulin resistance falls, homeostatic control is increasingly dominated by pancreatic release of insulin and glucagon, oscillations in blood glucose become increasingly prominent, and occur at progressively lower blood glucose levels.

86x58mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 6 - The y axis shows the value of  $t_{IG}$  at which model oscillations cease. For lower values the system oscillates.